Spravato
Six Years of Data: What the Longest Esketamine Study Shows About Safety
The SUSTAIN-3 study followed 1,148 adults on esketamine nasal spray for up to six and a half years. Here is what it found on side effects, blood pressure, bladder health, thinking and lasting benefit.
A First for Treatment-Resistant Depression: Esketamine Approved as a Stand-Alone Therapy
In January 2025 the FDA approved Spravato (esketamine) nasal spray for use on its own in adults with treatment-resistant depression. Here is what changed and what the trial showed.
OnlineTalk to ProviderCall us